Caesar J Belbel Net Worth

The estimated Net Worth of Caesar J Belbel is at least $185 Тысяча dollars as of 19 November 2015. Caesar Belbel owns over 153,333 units of Alaunos Therapeutics Inc stock worth over $184,905 and over the last 13 years Caesar sold ZIOP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Caesar Belbel ZIOP stock SEC Form 4 insiders trading

Caesar has made over 2 trades of the Alaunos Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Caesar exercised 153,333 units of ZIOP stock worth $352,666 on 19 November 2015.

The largest trade Caesar's ever made was exercising 153,333 units of Alaunos Therapeutics Inc stock on 19 November 2015 worth over $352,666. On average, Caesar trades about 16,140 units every 0 days since 2011. As of 19 November 2015 Caesar still owns at least 212,534 units of Alaunos Therapeutics Inc stock.

You can see the complete history of Caesar Belbel stock trades at the bottom of the page.

What's Caesar Belbel's mailing address?

Caesar's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY, INC.,, ONE FIRST AVE., BLDG. 34, BOSTON, MA, 02129.

Insiders trading at Alaunos Therapeutics Inc

Over the last 18 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk и Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.

What does Alaunos Therapeutics Inc do?

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

Complete history of Caesar Belbel stock trades at Alaunos Therapeutics Inc

Alaunos Therapeutics Inc executives and stock owners

Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include:

• Laurence Cooper,
  Chief Executive Officer, Director
• Satyavrat Shukla,
  Chief Financial Officer
• Robert Hadfield,
  Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
• Kevin Lafond,
  Senior Vice President - Finance, Chief Accounting Officer, Treasurer
• Heidi Hagen,
  Independent Director
• Dr. Eleanor de Groot Ph.D.,
  Exec. VP of Operations
• Christopher Bowden,
  Independent Director
• Scott Tarriff,
  Independent Chairman of the Board
• Dr. Raffaele Baffa M.D., Ph.D.,
  Chief Medical Officer and Exec. VP of R&D
• Elan Ezickson,
  Independent Director
• Zuie-Chin Huang M.B.A.,
  Exec. Chairman
• Mary Thistle,
  Independent Director
• Raffaele Baffa,
  Chief Medical Officer
• Christopher Taylor,
  Vice President, Investor Relations and Corporate Communications
• James Huang,
  Director
• J. Kevin Buchi,
  Director
• Lynn Ferrucci,
  Executive Vice President of Human Resources, Facilities, Administration and IT
• Eleanor De Groot,
  Executive Vice President, General Manager, Cell Therapy
• Jill Buck,
  Executive Vice President, General Manager, Gene Therapy
• Dr. Drew Deniger,
  Head of TCR-T Cell Therapy Program
• Dr. David M. Mauney M.D.,
  Consultant
• Melinda Lackey,
  Sr. VP of Legal
• Michael Wong,
  VP of Fin. & Principal Accounting Officer
• Timothy M. Cunningham CPA, M.B.A.,
  Interim CFO & Principal Financial Officer
• Kevin S. Boyle Sr.,
  CEO & Director
• James Anthony Cannon,
  Director
• Randal Jintrexon Corp Kirk,
  
• Murray Brennan,
  Director
• Wyche Fowler,
  Director
• Randal J Kirk,
  Director
• Caesar J Belbel,
  COO, CLO, and Secretary
• Michael Weiser,
  Director
• Francois Lebel,
  Executive Vice President R&D
• David M Md Mauney,
  President
• Douglas W. Pagan,
  Director
• Scott Braunstein,
  Director
• Hagop Youssoufian,
  Executive VP, CMO
• Timothy Mcinerney,
  Director
• Jonathan Lewis,
  CEO
• Jason Amello,
  Executive Vice President & CFO
• Richard E Bagley,
  President, COO & Treasurer
• George B Abercrombie,
  Director
• Robert Peter Gale,
  Senior V.P. of Research
• Lindsay A Md Rosenwald,
  10% owner
• Woodlands Health Ventures F...,
  10% owner
• Gary S Fragin,
  Director
• Sath Shukla,
  EVP, Chief Financial Officer
• Jaime Vieser,
  Director
• Holger Weis,
  Director
• Robert W Postma,
  Director
• Kevin S. Sr. Boyle,
  Chief Executive Officer
• Melinda Lackey,
  Senior Vice President, Legal